Central Retinal Vein Occlusion (CRVO)

Sponsor - Novartis (Recruitment/Not Yet Open)

RAVEN 
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT03810313?term=raven&rank=3
 

Sponsor - Patrick Higgins, MD (Recruitment/Open to Enrollment)

IST
Retrospective chart review of the prevalence of positive findings in the hypercoagulability workup on patients with ischemic and nonischemic retinal vein occlusions

Previous Central Retinal Vein Occlusion (CRVO) Study:

Sub-Investigator, 2008 - 2010
Sponsor: Genentech
Study: HORIZON
An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech-Sponsored Ranibizumab Study


Sub-Investigator, 2007 - 2010
Sponsor: Genentech
Study: CRUISE
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT00485836?term=CRUISE&rank=1